City of Hope Atlanta Urges Bold Action to Address Rise in Cancer Among Younger Women
City of Hope Atlanta, part of one of the largest and most advanced cancer research and treatment organizations in the United States, is calling for urgent change in light of surging cancer incidence among younger women. Central to the push:…
NCCN Guidelines Now Recommend FES PET for Lobular Breast Cancer
GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare’s…
Merck’s Zilovertamab Vedotin Shows Promising Results in Phase 2 DLBCL Trial
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and gemcitabine-oxaliplatin (R-GemOx)…
Parabilis to Present Phase 1/2 Data on FOG-001 at Medical Meetings
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced the presentations of trial-in-progress posters on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-cateninTCF4, at…
Bruker Launches Revolutionary timsOmniTM Mass Spectrometer
For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering…
Pfizer’s BRAFTOVI® Halves Death Risk in BRAF-Mutant Colon Cancer
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer…
CAR T Vision Coalition Aims to Double Patients Treated by 2030
international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients…
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in…
US Vaccines Market to Surpass $60B by 2033: Research Report
The “United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033” report has been added to ResearchAndMarkets.com’s offering. The United States vaccines market size was valued at USD 29.5 billion in 2024 and is projected to hit around…
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience…
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer…
Jewish Healthcare Foundation Releases Report on Self-Directed Patient Safety Technology
The technology exists for patients and families to prevent a medication error, understand what symptoms present a potentially serious condition, avoid an emergency room or hospital visit, schedule an appointment with a local specialist of high quality—all from their phone…